Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prana Biotechnology has received a composition of matter patent from the Japanese Patent Office (JPO) for its lead clinical asset, PBT2 and other selected 8-Hydroxyquinoline compounds.
Subscribe to our email newsletter
The patent entitled ‘8-Hydroxyquinoline derivatives’ also covers pharmaceutical compositions containing PBT2 and selected 8-hydroxyquinoline compounds and the use of the compounds for the treatment of Alzheimer’s disease.
Prana executive chairman Geoffrey Kempler said this decision by the Japanese Office to grant a claim to PBT2 completes a suite of core patent rights protecting this asset in key markets including the US, Europe, Japan and Australia, further bolstering their commercialization plans in both Huntington’s and Alzheimer’s disease.